

# REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED  
MAY 16 2001  
File Information Unit

In re Application of

Application Number

Filed

08/089407

7/8/93

Group Art Unit

Examiner

Paper No. 134

Assistant Commissioner for Patents  
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☒ (A) referred to in United States Patent Number 6013432, column 62,  
☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e.,  
Application No. \_\_\_\_\_, filed \_\_\_\_\_, on page \_\_\_\_\_ of  
paper number \_\_\_\_\_.  
☐ (C) an application that claims the benefit of the filing date of an application that is open to public  
inspection, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, or  
☐ (D) an application in which the applicant has filed an authorization to lay open the complete  
application to the public.

Please direct any correspondence concerning this request to the following address:

2000 Jefferson Davis Hwy suite 1109  
Arlington VA 22202  
Schwartz and Weinreb  
[Signature]  
Signature  
Geoff Thomas  
Typed or printed name

5/16/01  
Date

FOR PTO USE ONLY

Approved by: [Signature]  
(initials)

Unit: PTO



US006013432A

**United States Patent** [19]

Luciw et al.

[11] **Patent Number:** 6,013,432[45] **Date of Patent:** Jan. 11, 2000[54] **IMMUNOASSAY OF HIV ANTIBODIES  
USING RECOMBINANT OR SYNTHETIC  
SELECTED POL SEQUENCE**[75] Inventors: **Paul A. Luciw, Davis; Dino Dina**, San Francisco, both of Calif.[73] Assignee: **Chiron Corporation**, Emeryville, Calif.[21] Appl. No.: **08/443,434**[22] Filed: **May 17, 1995****Related U.S. Application Data**[62] Division of application No. 08/089,407, Jul. 8, 1993, which is a continuation of application No. 07/931,154, Aug. 17, 1992, which is a continuation of application No. 07/138,894, Dec. 24, 1987, Pat. No. 5,156,949, which is a continuation-in-part of application No. 06/773,447, Sep. 6, 1985, abandoned, which is a continuation-in-part of application No. 06/696,534, Jan. 30, 1985, abandoned, which is a continuation-in-part of application No. 06/667,501, Oct. 31, 1984, abandoned.[51] **Int. Cl.**<sup>7</sup> ..... **C12Q 1/70; G01N 33/53;**  
G01N 33/569; C12N 15/48[52] **U.S. Cl.** ..... **435/5; 435/7.1; 435/7.92;**  
435/69.3; 435/287.1; 435/320.1; 435/960;  
435/974; 530/300; 530/810; 530/806; 530/826;  
536/23.2[58] **Field of Search** ..... 435/320.1, 5, 7.1,  
435/69.3, 7.92, 287.1, 960, 974; 530/300,  
810, 826, 806; 536/23.2[56] **References Cited****U.S. PATENT DOCUMENTS**4,420,113 12/1983 Gallo .  
4,708,818 11/1987 Montagnier .  
4,716,102 12/1987 Levy .  
5,075,211 12/1991 Cosand ..... 435/5**FOREIGN PATENT DOCUMENTS**0 020 251 12/1980 European Pat. Off. .  
0 060 057 9/1982 European Pat. Off. .  
0 062 574 10/1982 European Pat. Off. .  
0 073 635 3/1983 European Pat. Off. .  
0 088 632 9/1983 European Pat. Off. .  
0 116 201 8/1984 European Pat. Off. .  
0 136 798 4/1985 European Pat. Off. .  
0 138 667 4/1985 European Pat. Off. .  
0 139 216 5/1985 European Pat. Off. .  
0 152 030 8/1985 European Pat. Off. .  
0 165 120 12/1985 European Pat. Off. .  
0 173 529 3/1986 European Pat. Off. .  
0 178 978 4/1986 European Pat. Off. .  
0 181 150 5/1986 European Pat. Off. .  
0 185 444 6/1986 European Pat. Off. .  
0 187 041 7/1986 European Pat. Off. .  
0 201 540 11/1986 European Pat. Off. .  
0 178 978 2/1992 European Pat. Off. .  
2104902 3/1983 United Kingdom .  
84/23659 9/1984 WIPO .  
84/16013 10/1984 WIPO .  
84/29099 11/1984 WIPO .  
85/01473 1/1985 WIPO .  
85/04897 11/1985 WIPO .  
85/04903 11/1985 WIPO .  
86/02383 4/1986 WIPO .

86/06414 11/1986 WIPO .

**OTHER PUBLICATIONS**Allan et al., *Science* (1985) 228:1091-1094.  
Amann et al., *Gene* (1983) 25:167-178.  
Barin et al., *Science* (1985) 228:1094-1096.  
Beardsley et al., *Nature* (1984) 311:195.  
Bolivar et al., *Gene* (1977) 2:95-113.  
Brun-Vezinet et al., *Lancet* (1984) 1253-1256.  
Casadban et al., *J. Bacteriology* (1980) 143(2):971-980.  
Chanda et al., *FASEB Proceedings* (1985) 44(5):1540.  
Chang et al., *J. Cell. Biochem.* (1985) 9A: 81 Abstract 0187.  
Chang et al., *Science* (1985) 228:93-96.  
Chang et al., *Nature* (1985) 315:151-154.  
Chang et al., *Bio/Technology* (1985) 3(10):905-909.  
*Chemical and Engineering News*, (1984) p. 7.  
Chen et al., *Nature* (1984) 309:276-279.  
Chen et al., *Nature* (1983) 305:502-505.  
Chermann et al., in Gottlieb et al. (eds. 1984) "Acquired Immune Deficiency Syndrome" UCLA Symposia on Molecular Biology, News Series, vol. 16 (1984) pp. 31-46.  
Clinica, *Abstract* (1984) p. 9.  
De Boer et al., *Proc. Natl. Acad. Sci.* (1983) 80:21-25.  
DiMaio et al., *Proc. Natl. Acad. Sci.* (1982) 79:4030-4032.  
Dina et al., *DNA* (1985) 4(1):56.  
Ellrodt et al., *Lancet* (1984) 1:1383-1385.  
Fisher et al., *Nature* (1985) 316:262-265.  
Fischinger et al., *Cancer Research* (1985) 45:4694s-4699s.  
French, T.J., *First Declaration of T.J. French* (1994).  
Gallo et al., in Gottlieb et al. Eds. (1984) pp. 47-58  
"Acquired Immune Deficiency Syndrome" UCLA Symposia on Molecular Biology, New Series (1984) 16:47-58.  
Gluzman et al., *Cell* (1981) 23:175-182.  
Gnann et al., *J. Virology* (1987) 61(8):2639-2641.  
Gray et al., *Proc. Natl. Acad. Sci.* (1982) 79:6598-6602.  
Groopman et al., *New Eng. J. Med.* (1984) 311(22):1419-1422.  
Hahn et al., *Nature* (1984) 312:166-169.  
Hattori et al., *Virology* (1984) 136:338-347.  
Huang et al., *DNA* (1985) 4(1):70.  
Karn et al., *Meth. Enzymology* (1983) 101:3-19.  
Kitchen et al., *Nature* (1984) 312:367-369.

(List continued on next page.)

**Primary Examiner**—Michael P. Woodward**Assistant Examiner**—Mary K. Zeman**Attorney, Agent, or Firm**—Dale H. Hoscheit; Alisa A. Harbin; Robert P. Blackburn[57] **ABSTRACT**

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

**25 Claims, 59 Drawing Sheets**